10:16 AM EST - InMed Pharmaceuticals Inc. : Announced it has received regulatory and ethics board approval of its Clinical Trial Application to conduct its second Phase 1 trial with INM-755. InMed Pharmaceuticals Inc.
shares T.IN are trading up $0.03 at $0.23.
